Overall survival in young adults with AML using different number of cycles of post-remission therapy. A. US Intergroup Study (ECOG E3489) for patients < 55 years; survival for patients who only received one cycle of post-remission therapy. Reproduced with permission from Cassileth PA, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med. 1998;339:1649–1656.10 B. CALGB 9222 for patients < 60 years; survival for patients who received 3 cycles of post-remission therapy. Reproduced with permission from Moore JO, et al. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. Blood. 2005;105:3420–3427.11
